At Rapafusyn, we are developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes. Rapafusyn has designed and generated large DNA encoded libraries (DELs) and arrayed libraries of non-degrading molecular glues (RapaGlues™) that are designed on a FKBP-binding macrocyclic peptide platform. These libraries have been successful in generating novel chemical starting points for hard-to-drug targets, often with cell permeability right from screening. Moreover, as our molecules are molecular glues, the target-binding peptidic portion is more tunable than traditional macrocyclic peptides. Our platform targets intracellular proteins and the intracellular domain of transmembrane proteins, such as SLCs and GPCRs. Our modular architecture, chemical, and biological capabilities enable rapid SAR expansion to optimize potency, selectivity, and physiochemical properties to accelerate drug discovery.
www.rapafusyn.com
